Zimmer BioTech Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $8.16M
Latest Deal Amount
  • Investors
  • 2

Zimmer BioTech General Information


Provider of drug research and development services intended to be used for the treatment of actinic keratoses in combination with photodynamic therapy. The company's platform offers a drug based on the compound 5-Aminolevulinic acid that is used to treat skin cancer, enabling doctors to treat patients effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Neu-Ulm
  • Germany
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zimmer BioTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 09-Aug-2017 $8.16M 00.000 000.00 Completed Startup
To view Zimmer BioTech’s complete valuation and funding history, request access »

Zimmer BioTech Executive Team (1)

Name Title Board Seat Contact Info
Armin Zimmer Chief Executive Officer
To view Zimmer BioTech’s complete executive team members history, request access »

Zimmer BioTech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
Zimmer MedizinSysteme Other Minority 000 0000 000000 0
To view Zimmer BioTech’s complete investors history, request access »